Panax notoginseng saponins inhibits NLRP3 inflammasome-mediated pyroptosis by downregulating lncRNA-ANRIL in cardiorenal syndrome type 4

Ying Xu,Luxi Cao,Wenli Zou,Rizhen Yu,Wei Shen
DOI: https://doi.org/10.1186/s13020-023-00756-2
IF: 4.546
2023-05-09
Chinese Medicine
Abstract:Cardiorenal syndrome type 4 (CRS4) is a complication of chronic kidney disease. Panax notoginseng saponins (PNS) have been confirmed to be efficient in cardiovascular diseases. Our study aimed to explore the therapeutic role and mechanism of PNS in CRS4.
pharmacology & pharmacy,integrative & complementary medicine
What problem does this paper attempt to address?